

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA RENJI
Medical Group Ltd.

中國仁濟醫療集團有限公司

CHINA RENJI MEDICAL GROUP LIMITED

中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

APPOINTMENT OF THE CHIEF MEDICAL OFFICER

The Board is pleased to announce that Mr. Ye Yukun has been appointed as the Chief Medical Officer of the Group effective from 17 December 2009.

The board of directors (the “Board”) of China Renji Medical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Mr. Ye Yukun (“Mr. Ye”) has been appointed as the Chief Medical Officer of the Group effective from 17 December 2009.

Mr. Ye, aged 66, is a famous specialist in thoracic tumor surgery. Mr. Ye has over 40 years of experience in clinical and scientific study of thoracic tumor and cardio-thoracic surgery and gained outstanding achievements in the study of early diagnosis of lung cancer. Mr. Ye is a general of civil service of the People’s Liberation Army of China (the “PLA”) and has been granted the status to receive special subsidy from the State Council of the People’s Republic of China (“China”). He was the vice-president of the 81st Hospital of the PLA* (中國人民解放軍第八一醫院) and the director and the chief doctor of the Tumor Research Centre of the PLA* (全軍腫瘤研究中心). Mr. Ye is currently a professor of surgery of the Faculty of Medicine in Nanjing University in China and a mentor of a doctoral program in the Second Military Medical University in China. Mr. Ye is also the deputy chairman of the Chinese Association of Thoracic Surgeons (中國胸外科醫師協會), a deputy director of the Committee of Oncology Specialists of the PLA* (全軍腫瘤學專業委員會) and the Jiangsu Society for Thoracic and Cardiovascular Surgery* (江蘇省胸心血管外科學會), a standing member of the Chinese Association of Tumor Hospital Management* (中華腫瘤醫院管理學會), the Tumor Marker Specialist Committee of the Chinese Anti-Cancer Association* (中國抗癌協會腫瘤標志專業委員會) and the International Association for Biologically Closed Electric Circuits in Medicine and Biology, a reviewing expert of the Technical Examination Committee of Medical Accident of the Chinese Medical Association* (中華醫學會醫療事故技術鑒定委員會) and a member of the International Association for the Study of Lung Cancer.

Mr. Ye will be responsible for the implementation and direction of the medical technology of the Group at the senior level and the academic exchange activities between the Group's medical centres and other hospitals. With Mr. Ye's expertise, academic platform and influence on the academic community in China, the management of the Company considers that the appointment of Mr. Ye will help the Group enhance the quality of clinical diagnosis offered by its medical centres and the scientific research and academic standards of the Group, and facilitate the partnership between its medical centres and hospitals.

The Board wishes to take this opportunity to extend its welcome to Mr. Ye for joining the Group.

By Order of the Board
China Renji Medical Group Limited
Li Juewen
Chairman

Hong Kong, 22 December 2009

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Li Juewen, Mr. Yu Chung Hang, Lucian and Mr. Guo Bao Ping; and three non-executive directors, namely Professor Wang Yongchang, Mr. Wu Zhenfang and Mr. Wang Hai; and three independent non-executive directors, namely Mr. Pang Wai Hong, Dr. Li Wing Chiu and Mr. Li Tieliu.

* *for identification purpose only*